Skip to main content

International Cancer Conference Journal

Ausgabe 1/2022

Inhalt (21 Artikel)

Editorial

Increasing our knowledge of germline variants

Noriomi Matsumura

Case report

Carotid body tumor with neck metastasis due to germline SDHB variant: a case report and literature review

Takuya Mikoshiba, Keisuke Yoshihama, Fumihiro Ito, Mariko Sekimizu, Shintaro Nakamura, Ryoto Nagai, Takenori Akiyama, Kentaro Matsubara, Hideaki Obara, Hiroyuki Ozawa

Case report

Germline variant of BRCA1 c.5332G>A has clinical features of hereditary breast and ovarian cancer syndrome

Chiaki Saita, Tomoyuki Aruga, Mio Adachi, Yuichi Kumaki, Naoko Iwamoto, Rika Yonekura, Noriko Nakatsugawa, Takuhiko Inokuchi, Toshiyuki Ishiba, Yayoi Honda, Tatsuro Yamaguchi

Case report

Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases

Suguru Hirose, Chiaki Enami, Natsumi Kawamatsu, Yoshimi Ito, Tsubasa Onoda, Yutaro Sugiyama, Hirosumi Suzuki, Miho Nagafuchi, Takafumi Ikeda, Yusuke Niisato, Takeshi Yamada, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Hideo Suzuki

Case report

A case of cardiac metastases from head and neck cancer presenting as hyperdense armored heart

Keitaro Fujii, Takayuki Imai, Yukinori Asada, Ikuro Sato, Tomoko Yamazaki, Kazuto Matsuura

Case report

Successful treatment with brentuximab vedotine for a patient with very late relapse of limited stage classic Hodgkin lymphoma

Jun Nukui, Hiroyuki Takahashi, Mayumi Tokunaga, Taisei Suzuki, Masaki Suzuki, Tomoyuki Yokose, Naoya Nakamura, Rika Sakai, Hideaki Nakajima

Case report

Laparoscopic hysterectomy for endometrial cancer after the Fontan procedure: The first case report

Yoshitsugu Chigusa, Shiro Baba, Koji Yamanoi, Haruko Okamoto, Yusuke Sagae, Masaki Mandai, Ken Yamaguchi

Open Access Case report

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Satoshi Furune, Chiaki Kondo, Yuko Takano, Tomoya Shimokata, Mihoko Sugishita, Ayako Mitsuma, Osamu Maeda, Yuichi Ando

Open Access Correction

Correction to: Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Satoshi Furune, Chiaki Kondo, Yuko Takano, Tomoya Shimokata, Mihoko Sugishita, Ayako Mitsuma, Osamu Maeda, Yuichi Ando

Case report

Successful laparoscopic conversion surgery for gastric cancer with para-aortic lymph node metastasis after third-line chemotherapy: a case report

Yuki Ushimaru, Kazuhiro Nishikawa, Yumiko Yasuhara, Ryohei Kawabata, Yoichi Makari, Junya Fujita, Akihiro Kitagawa, Nobuyoshi Ohara, Yuichiro Miyake, Sakae Maeda, Shin Nakahira, Ken Nakata, Atsushi Miyamoto

Case report

Appendiceal goblet cell adenocarcinoma with peritoneal recurrence 9 years after surgery

Masato Tamiya, Kenji Matsuda, Hiromitsu Iwamoto, Yasuyuki Mitani, Yuki Mizumoto, Yuki Nakamura, Toshihiro Sakanaka, Norio Takemoto, Takahiko Hyo, Ryuta Iwamoto, Hiroki Yamaue

Case report

Late recurrence of early gastric cancer 11 years after curative endoscopic submucosal dissection

Kei Iimori, Yasuyuki Tanaka, Shigehiko Fujii, Shinsuke Shibuya, Toshihiro Kusaka

Open Access Case report

Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

Yuko Takano, Satoshi Furune, Yuki Miyai, Sachi Morita, Megumi Inoue, Tomoya Shimokata, Mihoko Sugishita, Ayako Mitsuma, Osamu Maeda, Yuichi Ando

Case report

A case of Epstein–Barr virus-positive mucocutaneous ulcer of the hypopharynx: a mimicker of hypopharyngeal squamous cell carcinoma

Sota Masuoka, Takashi Hiyama, Hirofumi Kuno, Yohei Morishita, Shingo Sakashita, Tatsushi Kobayashi

Open Access Case report

A long-term survival case with proton beam therapy for advanced sphenoid sinus cancer with hypopituitarism

Yojiro Ishikawa, Motohisa Suzuki, Hisashi Yamaguchi, Ichiro Seto, Masanori Machida, Yoshiaki Takagawa, Keiichi Jingu, Yasuyuki Kikuchi, Masao Murakami

Case report

Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome

Tomohiro Matsumoto, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Daiki Taguchi, Hanae Shinozaki, Katsuhito Seki, Takayuki Yamanaka, Mako Ootaka, Hiroshi Nanjyo, Hiroyuki Watanabe, Hiroyuki Shibata

Case report

A rare case of intestinal lymphangiectasia induced by pazopanib

Kimihiko Masui, Yusuke Hama, Atsuro Sawada, Shusuke Akamatsu, Junya Sakaue, Makoto Okabe, Takashi Kobayashi

Open Access Case report

Radiation recall phenomenon after administration of the mRNA-1273 SARS-CoV-2 vaccine

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

Correction

Correction to: Letter to the editor on “Initial experience of laparoscopic radical nephrectomy using the Senhance® robotic system for renal cell carcinoma”

Tomislav Kuliš, Luka Penezić, Tvrtko Hudolin, Toni Zekulić, Hrvoje Saić, Nikola Knežević, Željko Kaštelan

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.